Study of Bortezomib and Revlimid™ for Patients Relapsing or Progressing on Total Therapy II

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2004
The purpose of this study is * to find out the effects of treating patients with two new chemotherapy drugs (bortezomib and Revlimid™), * to study how many patients\' myeloma responds to treatment on this study, and how many patients survive after this treatment, * to learn if a patient\'s genetic makeup before and after treatment can predict which patients will respond to bortezomib and Revlimid™, and to learn more about how the body responds (gene array studies).
Epistemonikos ID: f8ed8aa9840aae869188629e7e4ae50e91b2e93c
First added on: May 04, 2024